
|Articles|June 24, 2004
Organizations work to streamline approval of prostate cancer drugs
Four leading prostate cancer advocacy groups are working in cooperation with the FDA to streamline the approval process of critical prostate cancer treatments by changing clinical trial endpoints, without compromising safety.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











